PMV Pharmaceuticals, Inc. (PMVP) 10-Year Financial Performance & Capital Metrics

PMVP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutPMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.Show more

Revenue $0
EBITDA -$84M -6.9%
Net Income -$59M +14.9%
EPS (Diluted) -1.14 +21.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -29.23%
ROIC -37.96% -11.5%
Debt/Equity 0.01 -88.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-60.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.97%

ROCE

10Y Avg-28.1%

5Y Avg-26.49%

3Y Avg-33.33%

Latest-41.18%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	338K	388K	318K	1.28M	650K	1.26M	1.14M
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-338K	-388K	-318K	-1.28M	-650K	-1.26M	-1.14M
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.15%	0.18%	-3.03%	0.49%	-0.93%	0.09%
Operating Expenses+	18.89M	26.25M	34.62M	57.01M	76.39M	78.88M	84.3M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	5.04M	5.49M	11.01M	20.83M	24.72M	24.25M	26.92M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	13.85M	20.76M	23.61M	36.19M	51.67M	54.63M	57.38M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	16K	0	0	0	0	0	0
Operating Income+	-18.89M	-26.64M	-34.94M	-58.29M	-77.04M	-80.13M	-85.45M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.41%	-0.31%	-0.67%	-0.32%	-0.04%	-0.07%
EBITDA+	-18.55M	-26.25M	-34.62M	-57.01M	-76.39M	-78.88M	-84.3M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.41%	-0.32%	-0.65%	-0.34%	-0.03%	-0.07%
D&A (Non-Cash Add-back)	338K	388K	318K	1.28M	650K	1.26M	1.14M
EBIT	-18.89M	-25.34M	-34.43M	-57.82M	-73.33M	-68.96M	-74.81M
Net Interest Income+	0	1.3M	651K	449K	3.63M	11.17M	10.65M
Interest Income	1.34M	1.3M	651K	449K	3.63M	11.17M	10.65M
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	1.36M	1.29M	508K	470K	3.71M	11.17M	10.64M
Pretax Income+	-17.54M	-25.34M	-34.43M	-57.82M	-73.33M	-68.96M	-74.81M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	3K	8K	6K	23K	-9K	2K	-16.1M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.78%
Net Income+	-17.54M	-25.35M	-34.44M	-57.85M	-73.32M	-68.96M	-58.71M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.45%	-0.36%	-0.68%	-0.27%	0.06%	0.15%
Net Income (Continuing)	-17.54M	-25.35M	-34.44M	-57.85M	-73.32M	-68.96M	-58.71M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-5.80	-0.59	-2.40	-1.28	-1.61	-1.44	-1.14
EPS Growth %	-	0.9%	-3.07%	0.47%	-0.26%	0.11%	0.21%
EPS (Basic)	-5.80	-0.59	-2.40	-1.28	-1.61	-1.44	-1.14
Diluted Shares Outstanding	3.02M	43M	44.78M	45.14M	45.59M	48.01M	51.58M
Basic Shares Outstanding	3.02M	43M	44.78M	45.14M	45.59M	48.01M	51.58M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	62.24M	102.09M	364.76M	301.29M	247.01M	207.41M	175.66M
Cash & Short-Term Investments	61.91M	101.49M	361.42M	297.16M	241.05M	203.06M	169.45M
Cash Only	30.31M	73.28M	361.42M	172.47M	108.3M	37.71M	40.88M
Short-Term Investments	31.6M	28.21M	0	124.7M	132.76M	165.35M	128.58M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	3.34M	822K	5.95M	4.35M	6.2M
Total Non-Current Assets+	1.22M	940K	770K	30.28M	23.3M	44.74M	15.63M
Property, Plant & Equipment	1.02M	739K	569K	13.15M	20.49M	19.05M	1.55M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	16.91M	2.5M	25.5M	13.84M
Other Non-Current Assets	201K	201K	201K	221K	313K	190K	235K
Total Assets+	63.46M	103.03M	365.53M	331.57M	270.31M	252.15M	191.29M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	0.62%	2.55%	-0.09%	-0.18%	-0.07%	-0.24%
Total Current Liabilities+	2.33M	4.52M	6.41M	12.22M	10.83M	14.03M	14.37M
Accounts Payable	1.04M	2.84M	1.61M	3.19M	3M	3.24M	6.58M
Days Payables Outstanding	1.12K	2.67K	1.84K	908.65	1.68K	939.94	2.1K
Short-Term Debt	0	0	0	0	0	0	352K
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	3.8M	0	4.5M	5M
Current Ratio	26.75x	22.57x	56.90x	24.66x	22.80x	14.78x	12.22x
Quick Ratio	26.75x	22.57x	56.90x	24.66x	22.80x	14.78x	12.22x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	107.27M	168.98M	0	10.79M	13.45M	12.43M	838K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	10.79M	13.45M	12.43M	838K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	107.27M	168.98M	0	0	0	0	0
Total Liabilities	109.6M	173.51M	6.41M	23.01M	24.28M	26.46M	15.21M
Total Debt+	107.23M	0	0	11.19M	13.98M	13.29M	1.19M
Net Debt	76.92M	-73.28M	-361.42M	-161.27M	-94.32M	-24.42M	-39.69M
Debt / Equity	-	-	-	0.04x	0.06x	0.06x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-46.14M	-70.47M	359.12M	308.56M	246.03M	225.69M	176.08M
Equity Growth %	-	-0.53%	6.1%	-0.14%	-0.2%	-0.08%	-0.22%
Book Value per Share	-15.26	-1.64	8.02	6.84	5.40	4.70	3.41
Total Shareholders' Equity	-46.14M	-70.47M	359.12M	308.56M	246.03M	225.69M	176.08M
Common Stock	0	0	0	0	0	0	0
Retained Earnings	-50.09M	-75.44M	-109.88M	-167.73M	-241.04M	-310M	-368.71M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-13K	-3K	0	-78K	-445K	224K	139K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.18M	-22.07M	-32.74M	-46.57M	-63.76M	-55.66M	-51.28M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.45%	-0.48%	-0.42%	-0.37%	0.13%	0.08%
Net Income	-17.54M	-25.35M	-34.44M	-57.85M	-73.32M	-68.96M	-58.71M
Depreciation & Amortization	338K	388K	318K	1.28M	650K	1.26M	1.14M
Stock-Based Compensation	1.08M	908K	1.93M	0	0	12.38M	0
Deferred Taxes	319K	0	152K	0	0	0	0
Other Non-Cash Items	-13K	70K	143K	5.87M	9.47M	-5.76M	7.88M
Working Capital Changes	637K	1.92M	-845K	4.12M	-568K	5.43M	-1.59M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	267K	1.8M	-1.23M	191K	-389K	235K	3.34M
Cash from Investing+	21.69M	3.23M	27.91M	-143.58M	-1.37M	-50.55M	53.35M
Capital Expenditures	-452K	-109K	-148K	-1.35M	-7.98M	-962K	-655K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	22.14M	0	-148K	0	0	0	0
Cash from Financing+	0	61.8M	292.97M	2.02M	958K	35.58M	313K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	100K	6K	0	0	456K	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-15.63M	-22.17M	-32.89M	-47.92M	-71.74M	-56.62M	-51.94M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.42%	-0.48%	-0.46%	-0.5%	0.21%	0.08%
FCF per Share	-5.17	-0.52	-0.73	-1.06	-1.57	-1.18	-1.01
FCF Conversion (FCF/Net Income)	0.87x	0.87x	0.95x	0.81x	0.87x	0.81x	0.87x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	8K	6K	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-23.86%	-17.33%	-26.44%	-29.24%	-29.23%
Return on Invested Capital (ROIC)	-46.03%	-	-	-60.31%	-38.65%	-34.05%	-37.96%
Debt / Equity	-	-	-	0.04x	0.06x	0.06x	0.01x
FCF Conversion	0.87x	0.87x	0.95x	0.81x	0.87x	0.81x	0.87x

Frequently Asked Questions

Growth & Financials

PMV Pharmaceuticals, Inc. (PMVP) grew revenue by 0.0% over the past year. Growth has been modest.

PMV Pharmaceuticals, Inc. (PMVP) reported a net loss of $82.7M for fiscal year 2024.

Dividend & Returns

PMV Pharmaceuticals, Inc. (PMVP) has a return on equity (ROE) of -29.2%. Negative ROE indicates the company is unprofitable.

PMV Pharmaceuticals, Inc. (PMVP) had negative free cash flow of $73.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener